You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Jazz Pharma’s blood cancer therapy Rylaze wins US approval

The US Food and Drug Administration has approved Dublin-based Jazz Pharmaceutical’s Rylaze for the treatment of two blood cancers – acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL).